Saturday, December 16, 2017
 
 
News: Page (1) of 1 - 01/05/12 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Eli Lilly 2012 profit forecast misses expectations
Drugmaker Eli Lilly's 2012 profit forecast falls below analysts' expectations
By The Associated Press

INDIANAPOLIS (AP) ' Eli Lilly and Co. forecasts a steeper-than-expected earnings drop this year due to the expiration of a patent protecting its top-selling drug, the antipsychotic Zyprexa.

The Indianapolis drugmaker says it will earn between $3.10 and $3.20 per share in 2012. It expects Zyprexa revenue to plunge by over $3 billion. Zyprexa rang up more than $5 billion in 2010 sales. Its U.S. patent expired last fall, exposing it to cheaper generic competition.

Lilly's forecast falls well short of analysts' expectations. They forecast earnings of $3.60 per share in the new year. The company's 2012 prediction would mean a drop of between 26 percent and 28 percent from its forecast for earnings of $4.30 to $4.35 per share in 2011.



Shares fell $1.36, or 3.3 percent, to $39.35 in pre-market trading.


Page: 1


 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The U.S. Daily News - Contact Us - Advertise With Us - Privacy Guidelines